Search Result

Results for "

Stroke

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Adrenergic Receptor (10) Akt (17) Aminopeptidase (1) AMPK (1) Angiotensin Receptor (3) Antibiotic (6) Apoptosis (46) Aquaporin (1) Aryl Hydrocarbon Receptor (1) ASK1 (2) Aurora Kinase (1) Bacterial (4) Bcl-2 Family (3) Biochemical Assay Reagents (3) c-Fms (1) Calcium Channel (12) CaMK (1) Carbonic Anhydrase (1) Caspase (5) CaSR (2) Cathepsin (1) CDK (1) Cholinesterase (ChE) (3) Collagen (1) COX (2) CXCR (2) Cytochrome P450 (3) Deubiquitinase (1) Drug Derivative (2) Drug Isomer (1) Dynamin (1) E1/E2/E3 Enzyme (3) Endogenous Metabolite (7) Endothelin Receptor (3) Enolase (1) Epigenetic Reader Domain (1) ERK (2) Factor Xa (9) Ferroptosis (4) FKBP (1) FOXO (1) Fungal (1) GABA Receptor (4) Glutathione Peroxidase (4) Glycoprotein VI (1) GSK-3 (2) GSNOR (2) Hedgehog (1) Heme Oxygenase (HO) (1) Hexokinase (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Demethylase (4) HIV (2) HIV Integrase (1) HMG-CoA Reductase (HMGCR) (1) HSP (2) iGluR (16) Integrin (4) Interleukin Related (5) IRAK (1) Isotope-Labeled Compounds (13) Keap1-Nrf2 (8) Ligands for Target Protein for PROTAC (1) Liposome (1) Lipoxygenase (2) MAP3K (4) MDM-2/p53 (7) MEK (1) mGluR (2) Mitochondrial Metabolism (2) Mixed Lineage Kinase (3) MMP (2) Monoamine Oxidase (9) mTOR (1) nAChR (2) NADPH Oxidase (4) Necroptosis (1) Neuropeptide Y Receptor (1) NF-κB (5) NO Synthase (5) NOD-like Receptor (NLR) (2) NTPDase (1) Opioid Receptor (3) P2X Receptor (4) P2Y Receptor (2) p38 MAPK (5) p62 (2) PAI-1 (1) PARP (3) PCSK9 (1) PGC-1α (2) Phosphodiesterase (PDE) (6) Phospholipase (4) PI3K (7) Potassium Channel (10) PPAR (4) Prostaglandin Receptor (9) Proteasome (1) Pyroptosis (2) Quinone Reductase (2) Reactive Oxygen Species (ROS) (18) Reference Standards (24) Repulsive guidance molecule (1) RIP kinase (4) ROCK (1) ROS Kinase (4) SARS-CoV (1) Ser/Thr Protease (2) Sigma Receptor (3) Sirtuin (1) Sodium Channel (7) STAT (1) TGF-beta/Smad (2) Thrombin (15) TNF Receptor (2) Toll-like Receptor (TLR) (2) Trk Receptor (1) TRP Channel (8) TrxR (1) Wnt (6) α-synuclein (1) β-catenin (6)
By Research Areas:	Cancer (47) Cardiovascular Disease (104) Endocrinology (17) Infection (11) Inflammation/Immunology (48) Metabolic Disease (34) Neurological Disease (177)
Oligonucleotides:	Cationic Lipids (1)

258

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Hedgehog agonist 1	Hedgehog	Neurological Disease
Hh agonist 1 (compound 21k) is a potent Hedgehog (Hh) agonist, with an EC₅₀ 0.3 nM. Hh agonist 1 can be used for the research of stroke and other neurological disorders .

Tirilazad U 74006F free base	Antibiotic	Infection Neurological Disease
Tirilazad is a nonglucocorticoid, 21-aminosteroid that inhibits lipid peroxidation. Tirilazad can attenuate brain or spinal cord injury caused by trauma, stroke, ischemia and reperfusion injury. Tirilazad has antiviral activities against nCoV. Tirilazad is neuroprotective for ischaemic stroke, can be used for subarachnoid hemorrhage research .

GPI-1485 2 Publications Verification GM1485	FKBP	Neurological Disease
GPI-1485 (GM1485), a nonimmunosuppressive immunophilin ligand, promotes neurofunctional improvement and neural regeneration following stroke .

Ralpancizumab	PCSK9	Metabolic Disease
Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke .

MLN2201 YFC51.1; LDP-01	Integrin	Inflammation/Immunology
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .

Tirilazad mesylate U 74006F	Antibiotic	Infection Neurological Disease
Tirilazad mesylate (U 74006F) is a nonglucocorticoid, 21-aminosteroid that inhibits lipid peroxidation. Tirilazad mesylate can attenuate brain or spinal cord injury caused by trauma, stroke, ischemia and reperfusion injury. Tirilazad mesylate has antiviral activities against nCoV. Tirilazad mesylate is neuroprotective for ischaemic stroke, can be used for subarachnoid hemorrhage research .

Tirilazad mesylate hydrate U 74006F hydrate	Antibiotic	Infection Metabolic Disease
Tirilazad mesylate hydrate is the hydrate form of Tirilazad mesylate (HY-122070). Tirilazad mesylate is a nonglucocorticoid, 21-aminosteroid that inhibits lipid peroxidation. Tirilazad mesylate can attenuate brain or spinal cord injury caused by trauma, stroke, ischemia and reperfusion injury. Tirilazad mesylate has antiviral activities against nCoV. Tirilazad mesylate is neuroprotective for ischaemic stroke, can be used for subarachnoid hemorrhage research .

PSB-6426	NTPDase	Cancer
PSB-6426 (compund 19a) is a selective human NTPDase2 inhibitor (K_i=8.2 μM). PSB-6426 can be used in stroke and cancer research .

Neuroprotective agent 4	Others	Neurological Disease
Neuroprotective agent 4 (compound 24a) is a novel and effective small molecule antioxidant. Neuroprotective agent 4 has a neuroprotective effect. Neuroprotective agent 4 can be used in the study of ischemic stroke and related diseases .

Edaravone dimer impurity	Drug Derivative	Neurological Disease
Edaravone dimer impurity (Dimer 2) is a stable conjugated Edaravone (HY-B0099) dimer. Edaravone is a free radical scavenging agent for the study of acute ischemic stroke .

Thrombin-cleavable peptide	Thrombin	Cardiovascular Disease Neurological Disease
Thrombin-cleavable peptide is a type of peptide that can be recognized and cleaved by thrombin. After cleavage, Thrombin-cleavable peptide releases thrombolytic peptides to initiate thrombolysis. Thrombin-cleavable peptide can be used in the research of diseases such as ischemic stroke .

MRS4596	P2X Receptor	Neurological Disease
MRS4596 is a potent and selective P2X4 receptor antagonist with an IC₅₀ value of 1.38 μM for human P2X4 receptor. MRS4596 has neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4596 can be used in research of ischemic stroke .

Tenecteplase TNK-tPA	Ser/Thr Protease	Cardiovascular Disease
Tenecteplase (TNK-tPA) is a modified tissue plasminogen activator. Tenecteplase is a recombinant human tissue plasminogen activator (rt-PA) that has been bioengineered to produce mutations in three gene loci. Tenecteplase (TNK-tPA) can be used in the study of acute ischemic stroke .

Gavestinel sodium salt GV 150526A	iGluR	Cardiovascular Disease
Gavestinel (GV 150526A) is a potent, selective, orally active and non-competitive antagonist of NMDA receptor. Gavestinel binds to the glycine site of the NMDA receptor, with a pK_i of 8.5. Gavestinel can be used for the research of acute ischemic stroke .

5-LOX-IN-3	Lipoxygenase	Neurological Disease Inflammation/Immunology Cancer
5-LOX-IN-3 (Compound 14) is a 5-Lipoxygenase inhibitor (IC₅₀: <1 μM). 5-LOX-IN-3 can be used for research of inflammatory diseases, cancer, stroke and Alzheimer's disease .

β-Funaltrexamine hydrochloride β-FNA hydrochloride	Opioid Receptor NO Synthase	Neurological Disease Inflammation/Immunology
β-Funaltrexamine (β-FNA) hydrochloride is a selective μ opioid receptor antagonist. β-Funaltrexamine hydrochloride also inhibits cytokine-induced iNOS activation. β-Funaltrexamine hydrochloride inhibits neuroinflammation and ameliorated neuronal degeneration. β-Funaltrexamine hydrochloride has anti-inflammatory and neuroprotective effects and can be used for research of neurodegenerative diseases (eg: stroke) ^{[1] ^{^[2]}}

TRC051384 hydrochloride	HSP	Cardiovascular Disease Neurological Disease
TRC051384 hydrochloride is a potent inducer of heat shock protein 70 (HSP70). TRC051384 hydrochloride exhibits protective effects against neuronal trauma via inhibition of necroptosis. TRC051384 hydrochloride can be used for the research of ischemic stroke .

GABA-A Receptor Ligand-1	GABA Receptor	Neurological Disease
GABA-A Receptor Ligand-1 (Compound 4) is a ligand for GABA-A receptor with a pK_i of 7.27. GABA-A Receptor Ligand-1 reduces mitochondrial dysfunction, promotes neurite outgrowth and neuronal regeneration. GABA-A Receptor Ligand-1 exhibits neuroprotective efficacy in rats ischemic stroke models .

AER-271 1 Publications Verification	Aquaporin	Cardiovascular Disease Neurological Disease
AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 (AQP4) inhibitor for the research of acute ischemic stroke .

ATF3-IN-1	Ferroptosis Epigenetic Reader Domain Reactive Oxygen Species (ROS) Glutathione Peroxidase	Cardiovascular Disease Neurological Disease
ATF3-IN-1 is a ferroptosis and ATF3 inhibitor. ATF3-IN-1 inhibits oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, exerting anti-ischemic stroke effects. ATF3-IN-1 can attenuate ischemia/reperfusion (I/R) injury and improve neuronal survival. ATF3-IN-1 has neuroprotective effects and can be used to study ischemic stroke .

Oxeladin citrate	Sigma Receptor	Cardiovascular Disease Others Neurological Disease
Oxeladin citrate is an orally active and brain-penetrant cough suppressant as well as a selective sigma 1 receptor agonist (K_i = 25 nM). Oxeladin can be used for pulmonary diseases and stroke research .

BMS-191011 3 Publications Verification BMS-A	Potassium Channel	Neurological Disease
BMS 191011 (BMS-A) is a potent BK_Ca channel opener (large-conductance Ca ²⁺-activated potassium channel). BMS-191011 shows neuroprotective activities in rodent models of stroke .

Neuroprotective agent 1	Drug Derivative	Cardiovascular Disease
Neuroprotective agent 1 (2), a promising neuroprotective agent for the study of ischemic stroke, shows promising neuroprotective activity with the EC₅₀ value of 16.07 μM in the model of glutamate-induced excitotoxicity and 19.30 μM in the model of H₂O₂-induced oxidative damage .

GSNOR-IN-2	GSNOR	Neurological Disease
GSNOR-IN-2 (Compound 45) is a S-nitrosoglutathione reductase (GSNOR) inhibitor with an IC₅₀ of 44.12 nM. GSNOR-IN-2 has neuroprotective activity, promising for ischemic stroke research .

OY-201	Others	Neurological Disease
OY-201 is a potential and BBB-penetrated anti-ischemic stroke agent. OY-201 shows the good safety and neuroprotective activity in both in vitro and in vivo models .

MRS4719	P2X Receptor	Neurological Disease
MRS4719 is a potent P2X4 receptor antagonist with an IC₅₀ value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca ²⁺]_i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .

Cinepazide	Calcium Channel	Cardiovascular Disease
Cinepazide is a piperazine derivative and acts as a weak calcium channel blocker. Cinepazide is a potent vasodilator and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain infarct et. al .

TC-G 24	GSK-3	Neurological Disease Metabolic Disease
TC-G 24 (Compound 24) is a potent, selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC₅₀ of 17.1 nM. TC-G 24 can cross the BBB and can be used for studying many diseases such as type 2 diabetes mellitus, stroke, Alzheimer, and other related diseases .

LY836	iGluR	Neurological Disease
LY836 is an orally active neuroprotective agent. LY836 significantly blocks PSD95-nNOS association in cortical neurons. LY836 can be used in study ischemic stroke .

NS1219 (R)-SPD502	iGluR	Neurological Disease
NS1219 ((R)-SPD502) is the isomer of NS 1209 HY-15074. NS1209 is a selective AMPA receptor antagonist with neuroprotective activity. NS1209 can be used for the research of stroke, neuropathic pain and epilepsy .

α5β1 integrin agonist-2	Integrin Akt ERK	Cardiovascular Disease
α5β1 integrin agonist-2 (Compound 2) is a highly selective α5β1 integrin agonist (EC₅₀=45.98 nM). α5β1 integrin agonist-2 enhances extracellular matrix adhesion and Akt/ERK signaling activation. α5β1 integrin agonist-2 is promising for research of ischemic stroke .

Tanshinone IIB	Apoptosis	Cardiovascular Disease Neurological Disease
Tanshinone IIB is a major active constituent of the roots of Salvia miltiorrhiza (Danshen) widely used for the research of stroke and coronary heart disease in Asian countries. Tanshinone IIB has a neuroprotective effect via inhibition of apoptosis .

Cinepazide Maleate MD-67350	Calcium Channel	Cardiovascular Disease
Cinepazide Maleate (MD-67350) is a piperazine derivative and acts as a weak calcium channel blocker. Cinepazide Maleate is a potent vasodilator and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain?infarct et. al .

Anti-apoptotic agent 1	Apoptosis	Neurological Disease
Anti-apoptotic agent 1 (Compound B4) exhibits neuroprotective activity and good pharmacokinetic properties. Anti-apoptotic agent 1 inhibits apoptosis, prevents stroke recurrence in photothrombotic rat model .

PF-03049423	Phosphodiesterase (PDE)	Neurological Disease
PF-03049423 (Compound PF-5) is a potent and highly selective phosphodiesterase-5A inhibitor with an IC₅₀ of about 0.2 nM for rat and human platelet enzyme. PF-03049423 can be used for the research of acute ischaemic stroke .

Oxeladin citrate (Standard)	Reference Standards Sigma Receptor	Cardiovascular Disease Others Neurological Disease
Oxeladin (citrate) (Standard) is the analytical standard of Oxeladin (citrate). This product is intended for research and analytical applications. Oxeladin citrate is an orally active and brain-penetrant cough suppressant as well as a selective sigma 1 receptor agonist (Ki = 25 nM). Oxeladin can be used for pulmonary diseases and stroke research .

PF-03049423 free base	Phosphodiesterase (PDE)	Neurological Disease
PF-03049423 (Compound PF-5) free base is a potent and highly selective phosphodiesterase-5A inhibitor with an IC₅₀ of about 0.2 nM for rat and human platelet enzyme. PF-03049423 free base can be used for the research of acute ischaemic stroke .

TAT-EE3	TRP Channel iGluR Calcium Channel	Neurological Disease
TAT-EE3 is a neuroprotective peptide which can uncouple TRPM2-NMDARs interaction. TAT-EE3 inhibits TRPM2-induced enhancement of NMDAR surface expression and current amplitude.TAT-EE3 protects neurons against ischemic injury in vitro and in vivo. TAT-EE3can be used for the study of ischemic stroke .

NT1-014B	Liposome Biochemical Assay Reagents	Cardiovascular Disease Neurological Disease
NT1-014B is a tryptamine-derived lipidoid. NT1-014B incorporates NT-lipidoid into BBB-impermeable lipid nanoparticles (LNPs), enabling the LNPs to cross the BBB. NT1-014B enhances brain delivery via intravenous injection. NT1-014B can be used in ischemic stroke research .

Pentifylline 1-Hexyltheobromine; Hexyltheobromine	Collagen	Cardiovascular Disease
Pentifylline is a vasodilator with anti-inflammatory activity. Pentifylline inhibits platelet aggregation and thromboxane A2 synthesis, reduces the release of free radicals, and decreases the production of type 1 collagen and laminin in fibroblasts. Pentifylline has the potential to be studied in acute ischemic stroke .

TRPM2-IN-1	TRP Channel	Neurological Disease
TRPM2-IN-1 (compound D10) is a potent TRPM2 inhibitor. TRPM2-IN-1 exhibits antistroke activity and significant neuroprotective effect. TRPM2-IN-1 can be used in the study of ischemic stroke .

BRL 52537 hydrochloride	Opioid Receptor	Neurological Disease
BRL 52537 hydrochloride is a highly selective κ-Opioid receptor (KOR) agonist with K_is of 0.24 nM and 1560 nM for κ and μ subtypes, respectively. BRL 52537 hydrochloride decreases ischemia-evoked NO production as a potential mechanism of neuroprotection. BRL 52537 hydrochloride attenuates early stroke damage .

Neuroprotective agent 8	Reactive Oxygen Species (ROS) PGC-1α NOD-like Receptor (NLR)	Neurological Disease
Neuroprotective agent 8 (compound AA-9) is an oral active neuroprotective agent by anti-oxidative stress and anti-inflammation. Neuroprotective agent 8 activates PGC-1α and inhibits NLRP3 in the rat MCAO ischemic stroke model .

Pinokalant LOE-908	TRP Channel SARS-CoV	Neurological Disease
Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity .

Amelparib hydrochloride JPI-289 hydrochloride	PARP	Cardiovascular Disease Neurological Disease
Amelparib (JPI-289) hydrochloride is a potent, orally active, and water-soluble inhibitor of PARP-1. Amelparib hydrochloride inhibits PARP-1 activity (IC₅₀ = 18.5 nM) and cellular PAR formation (IC₅₀ = 10.7 nM). Amelparib hydrochloride is a potential neuroprotective agent. Amelparib hydrochloride has the potential for the research of acute ischaemic stroke .

A2A/A1 AR antagonist-1	Adenosine Receptor	Neurological Disease
A2A/A1 AR antagonist-1 (compound 1a) is dual potent A_2A/A₁ AR antagonist with K_is of 5.58 and 24.2 nM, respectively. A2A/A1 AR antagonist-1 has the potential for the research of ischemic stroke .

Cat. No.	Product Name

HY-L003

Apoptosis Compound Library

3,062 compounds

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.

MCE designs a unique collection of 3,062 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

HY-L046

Anti-Cardiovascular Disease Compound Library

2,009 compounds

Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk.

MCE supplies a unique collection of 2,009 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

HY-L087

Anti-Obesity Compound Library

3,049 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 3,049 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

HY-L013

Neuronal Signaling Compound Library

3,329 compounds

Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.

MCE designs a unique collection of 3,329 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

Cat. No.	Product Name	Type

HY-137500

NT1-014B	Drug Delivery
NT1-014B is a tryptamine-derived lipidoid. NT1-014B incorporates NT-lipidoid into BBB-impermeable lipid nanoparticles (LNPs), enabling the LNPs to cross the BBB. NT1-014B enhances brain delivery via intravenous injection. NT1-014B can be used in ischemic stroke research .

HY-D0714

Tetrazolium Red

5 Publications Verification

2,3,5-Triphenyltetrazolium chloride; TPTZ; TTC

Enzyme Substrates

Tetrazolium Red (2,3,5-Triphenyltetrazolium chloride; TTC) is a not brain-penetrant, colorless, water-soluble dye that is reduced by mitochondrial enzymes to a deep red, water-insoluble compound (formazan) mainly in the mitochondria of living cells. Tetrazolium Red is used to observe the activity of dehydrogenase, and it turns colorless to red when exposed to hydrogen. Tetrazolium Red distinguishes between surviving and infarcted brain tissue after stroke. Tetrazolium Red has been used to stain heart tissue to measure the extent of acute lesions and also used to stain brain tissue to detect the size of the infarcted area. The absorption wavelength of Tetrazolium Red is 570 nm .

HY-NP001

Cationic Bovine Serum Albumin

1 Publications Verification

CBSA

Native Proteins

Cationic Bovine Serum Albumin is a bovine serum albumin (BSA) modified with excess ethylenediamine, which has enhanced immunogenicity compared to native BSA. Positively charged primary amines block all negatively charged carboxyl groups, making Cationic Bovine Serum Albumin a cationic protein. Cationic Bovine Serum Albumin has remarkable neuroprotective effects on ischemic stroke when in combination with Tanshinone IIA (HY-N0135) .

Cat. No.	Product Name	Target	Research Area

HY-P3709A

TRAF6 peptide TFA	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide TFA is a specific TRAF6-p62 inhibitor. TRAF6 peptide TFA potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide TFA has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P11049

Stroke-homing peptide	Peptides	Neurological Disease
Stroke-homing peptide is a homing peptide. Stroke-homing peptide can home to ischemic stroke brain tissue and detect the apoptotic neuronal cells. Stroke-homing peptide can be used for the research of molecular imaging and selective drug delivery to stroke tissue .

HY-P11048

Thrombin-cleavable peptide	Thrombin	Cardiovascular Disease Neurological Disease
Thrombin-cleavable peptide is a type of peptide that can be recognized and cleaved by thrombin. After cleavage, Thrombin-cleavable peptide releases thrombolytic peptides to initiate thrombolysis. Thrombin-cleavable peptide can be used in the research of diseases such as ischemic stroke .

HY-P11117

TAT-EE3	TRP Channel iGluR Calcium Channel	Neurological Disease
TAT-EE3 is a neuroprotective peptide which can uncouple TRPM2-NMDARs interaction. TAT-EE3 inhibits TRPM2-induced enhancement of NMDAR surface expression and current amplitude.TAT-EE3 protects neurons against ischemic injury in vitro and in vivo. TAT-EE3can be used for the study of ischemic stroke .

HY-P3709

TRAF6 peptide	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P5117

TAT-CIRP	Toll-like Receptor (TLR)	Neurological Disease
TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. TAT-CIRP is an inhibitor of myeloid differentiation protein 2 (MD2). TAT-CIRP exhibits robust neuroprotection against ischemic and hemorrhagic stroke in mice .

HY-P10275

Tat-NTS peptide	Apoptosis	Neurological Disease
Tat-NTS peptide is a cell-penetrating peptide with neuroprotective effects. Tat-NTS peptide can specifically inhibit the nuclear translocation of ANXA1 and reduce neuronal apoptosis in ischemic areas. Moreover, Tat-NTS peptide can reduce the volume of cerebral ischemic infarction and can be used in the research of ischemic stroke .

HY-P10977

Tat-ASIC1a (1-20) (mouse, rat)	Sodium Channel RIP kinase	Neurological Disease
Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a membrane-penetrating peptide. Tat-ASIC1a (1-20) (mouse, rat) has significantly neuroprotection effects, and reduces neuronal damage against acidotoxicity by targeting the ASIC1a-RIPK1 pathway and auto-inhibitory mechanism. Tat-ASIC1a (1-20) (mouse, rat) effectively protects brains from ischemic injury in ischemic stroke mice model. Tat-ASIC1a (1-20) (mouse, rat) can be used for neurodegenerative diseases research, such as Huntington disease and Parkinson’s disease .

HY-P10854

TAT-N15	NF-κB Interleukin Related STAT Akt	Neurological Disease Inflammation/Immunology
TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke .

HY-P1949

Cyclic MKEY	CXCR	Cardiovascular Disease Cancer
Cyclic MKEY is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY also protects against stroke-induced brain injury in mice .

HY-P1949A

Cyclic MKEY TFA	CXCR	Cardiovascular Disease Cancer
Cyclic MKEY TFA is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY TFA also protects against stroke-induced brain injury in mice .

HY-P1428A

RFRP-1(human) TFA	Neuropeptide Y Receptor	Cardiovascular Disease
RFRP-1(human) TFA is a potent endogenous NPFF receptor agonist (EC₅₀ values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, ejection fraction and cardiac output, and increases plasma prolactin levels in rats.

HY-P5883

TAT-M2NX tatM2NX	TRP Channel	Neurological Disease
TAT-M2NX (tatM2NX) is a TRPM2 inhibitor with specific neuroprotective activity in male mice. TAT-M2NX can be used to study ischemic neuronal damage .

HY-P5754B

TAT-NEP1-40 acetate	Apoptosis	Neurological Disease
TAT-NEP1-40 acetate is a therapeutic candidate for axonal regeneration and functional recovery after stroke. TAT-NEP1-40 acetate can protect PC12 cells against oxygen and glucose deprivation (OGD) and promote neurite outgrowth. TAT-NEP1-40 acetate protects the brain against ischemia/reperfusion injury through inhibition of neuronal apoptosis. TAT-NEP1-40 acetate can be efficiently delivered into the rat brains .

HY-P5754

TAT-NEP1-40	Apoptosis	Neurological Disease
TAT-NEP1-40 is a BBB-penatrable peptide. TAT-NEP1-40 protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .

HY-P3012

Cathepsin G	Cathepsin	Inflammation/Immunology
Cathepsin G acts as a potent agonist of human platelet activation leading to their aggregation., and can be used for screening of relevant inhibitors .

HY-P5754A

TAT-NEP1-40 TFA	Apoptosis	Neurological Disease
TAT-NEP1-40 TFA is a BBB-penatrable peptide. TAT-NEP1-40 TFA protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 TFA also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 TFA can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .

HY-P5947

Tat-HA-NR2B9c	HIV	Neurological Disease
Tat-HA-NR2B9 contains a fragment of the cellmembrane transduction domain of HIV-1 Tat, a influenza virus hemagglutinin (HA) epitope-tag, and the C-terminal 9 amino acids of NR2B (NR2B9c). Tat-HA-NR2B9 reduces infarct size and improves neurological functions in ischemia-induced cerebral injury in the rats

HY-P10368

P110 heptapeptide	Dynamin Reactive Oxygen Species (ROS)	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
P110 heptapeptide is a peptide inhibitor of the Drp1-Fis1 interaction. P110 heptapeptide has anti-inflammatory, immunomodulatory, mitochondrial protective, and neuroprotective activities. Without blocking the physiological functions of Drp1, P110 heptapeptide reduces pathological functions in many models of neurodegeneration, ischemia, and sepsis. P110 heptapeptide can be used for research on neurological and inflammatory diseases .

Cat. No.	Product Name	Target	Research Area

HY-P99891

Rovelizumab 1 Publications Verification	Integrin	Cardiovascular Disease
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .

HY-P99403

Refanezumab GSK249320	Inhibitory Antibodies	Neurological Disease
Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke .

HY-P99644

ACT017 1 Publications Verification	Glycoprotein VI	Cardiovascular Disease
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke .

HY-P99336

Enlimomab BI-RR 0001; Anti-Human IL6 Recombinant Antibody	Integrin	Neurological Disease Inflammation/Immunology
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .

HY-108841

Raleukin Maximum Cited Publications 44 Publications Verification Kineret; Anakinra	Interleukin Related	Inflammation/Immunology Cancer
Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction .

HY-P990125

Anti-Mouse CSF1R/CD115 Antibody (AFS98)	c-Fms	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Anti-Mouse (CSF1R/CD115) Antibody (AFS98) is an anti-mouse CSF1R IgG2a antibody inhibitor derived from rats. Anti-Mouse (CSF1R/CD115) Antibody (AFS98) inhibits M-CSF-dependent colony formation and cell growth by blocking the binding of M-CSF to its receptor. Anti-Mouse (CSF1R/CD115) Antibody (AFS98) can be used for the researches of inflammation, metabolic disease, cardiovascular disease and neurological disease, such as such as stroke, diabetes and arthritis .

HY-P99816

Ralpancizumab	PCSK9	Metabolic Disease
Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke .

HY-P991604

MLN2201 YFC51.1; LDP-01	Integrin	Inflammation/Immunology
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .

HY-P991422

Stromab DS9231; TS-23; CSL-301	PAI-1	Cardiovascular Disease
Stromab (DS9231; TS-23; CSL-301) is a human IgG1 monoclonal antibody (mAb) targeting Serpin F2. Stromab can be used in schaemic stroke, Pulmonary embolism, Myocardial infarction and Thrombosis research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .

HY-P991716

Selcodebart	Repulsive guidance molecule	Neurological Disease Metabolic Disease Cancer
Selcodebart is a humanized IgG1κ monoclonal antibody inhibitor targeting Repulsive Guidance Molecule C (RGMC/HFE2). Selcodebart has antianaemic activity. Abdakibart can be used for CNS disorders like Alzheimer’s disease and stroke, brain tumors and anemia research .

Cat. No.	Product Name	Chemical Structure

HY-10274S

Dabigatran etexilate-d13
Dabigatran etexilate-d₁₃ is the deuterium labeled Dabigatran etexilate. Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran. Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .

HY-10264S

Edoxaban-d6

Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .

HY-151546S

MRS4596-d4
MRS4596-d₄ is the deuterium labeled MRS4596 (HY-151546). MRS4596 is a potent and selective P2X4 receptor antagonist with an IC₅₀ value of 1.38 μM for human P2X4 receptor. MRS4596 has neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4596 can be used in research of ischemic stroke .

HY-B0647S1

Butylphthalide-d3
Butylphthalide-d₃ is the deuterium labeled Butylphthalide. Butylphthalide(3-n-Butylphthalide), an anti-cerebral-ischemia agent, is first isolated from the seeds of celery and showes efficacy in animal models of stroke.

HY-151547S

MRS4719-d3

MRS4719-d₃ is the deuterium labeled MRS4719 (HY-151547). MRS4719 is a potent P2X4 receptor antagonist with an IC₅₀ value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca ²⁺]_i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .

HY-W744643

Butylphthalide-d9
Butylphthalide-d₉ (3-n-Butylphthalide-d₉) is deuterium labeled Butylphthalide. Butylphthalide (3-n-Butylphthalide) is an active molecule against cerebral ischemia. It was originally isolated from celery species and has been shown to be effective in stroke animal models .

HY-W705434

Dabigatran etexilate-d11
Dabigatran etexilate-d₁₁ (BIBR 1048-d₁₁) is the deuterium labeled Dabigatran etexilate (HY-10274). Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .

HY-14914S1

Azilsartan-d4
Azilsartan-d₄ is the deuterium labeled Azilsartan . Azilsartan is an orally active, potent, selective and specific angiotensin II type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research .

HY-N0361S

Dihydrocapsaicin-d3

Dihydrocapsaicin-d₃ is the deuterium labeled Dihydrocapsaicin (HY-N0361) . Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat .

HY-70057S1

Safinamide-d4-1

Safinamide-d₄-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 μM) over MAO-A (IC₅₀=580 μM) . Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8?μM) than at resting (IC₅₀=262?μM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al .

HY-70057S4

Safinamide-d5

Safinamide-d₅ (FCE 26743-d₅) is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 μM) over MAO-A (IC₅₀=580 μM) . Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8?μM) than at resting (IC₅₀=262?μM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al .

HY-B1018AS

Phenelzine-d5 sulfate

Phenelzine-d₅ sulfate is the deuterium labeled Phenelzine sulfate (HY-B1018A). Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (K_i: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer .

HY-B0194S

Tizanidine-d4

Tizanidine-d₄ is the deuterium labeled Tizanidine (HY-B0194). Tizanidine, a skeletal muscle relaxant, is an orally effective central α₂-adrenoceptor agonist (IC₅₀ = 6.9 nmol). Tizanidine primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-B0194AS

Tizanidine-d4 hydrochloride

Tizanidine-d₄ hydrochloride is deuterium labeled Tizanidine hydrochloride (HY-B0194A). Tizanidine hydrochloride, a skeletal muscle relaxant, is an orally effective central α₂-adrenoceptor agonist (IC₅₀ = 6.9 nmol). Tizanidine hydrochloride primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine hydrochloride has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine hydrochloride can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine hydrochloride can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).

HY-W027553S1

Ipidacrine-d9

Ipidacrine-d₉ (NIK-247-d₉ (free base)) is the deuterium labeled Ipidacrine (HY-W027553). Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC₅₀ values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K+ and Na+-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .

Cat. No.	Product Name		Classification